Biotage Ab Stock Cash And Equivalents
| BIOT Stock | SEK 102.20 1.10 1.06% |
Biotage AB fundamentals help investors to digest information that contributes to Biotage AB's financial success or failures. It also enables traders to predict the movement of Biotage Stock. The fundamental analysis module provides a way to measure Biotage AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotage AB stock.
Biotage |
Biotage AB Company Cash And Equivalents Analysis
Biotage AB's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Biotage AB Cash And Equivalents | 311 M |
Most of Biotage AB's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotage AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Biotage AB has 311 M in Cash And Equivalents. This is 62.11% lower than that of the Life Sciences Tools & Services sector and about the same as Health Care (which currently averages 313.97 M) industry. The cash and equivalents for all Sweden stocks is 88.49% higher than that of the company.
Biotage Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotage AB's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotage AB could also be used in its relative valuation, which is a method of valuing Biotage AB by comparing valuation metrics of similar companies.Biotage AB is currently under evaluation in cash and equivalents category among its peers.
Biotage Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 12.84 B | |||
| Shares Outstanding | 65.98 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 64.57 % | |||
| Price To Earning | 38.27 X | |||
| Price To Book | 8.12 X | |||
| Price To Sales | 8.04 X | |||
| Revenue | 1.23 B | |||
| Gross Profit | 755 M | |||
| EBITDA | 347 M | |||
| Net Income | 269 M | |||
| Cash And Equivalents | 311 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 180 M | |||
| Debt To Equity | 26.40 % | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 24.23 X | |||
| Cash Flow From Operations | 353 M | |||
| Earnings Per Share | 3.73 X | |||
| Target Price | 229.33 | |||
| Number Of Employees | 510 | |||
| Beta | 0.81 | |||
| Market Capitalization | 10.45 B | |||
| Total Asset | 1.99 B | |||
| Retained Earnings | 541 M | |||
| Working Capital | 212 M | |||
| Current Asset | 327 M | |||
| Current Liabilities | 115 M | |||
| Z Score | 34.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.62 % | |||
| Net Asset | 1.99 B | |||
| Last Dividend Paid | 1.55 |
About Biotage AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotage AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotage AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotage AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biotage Stock Analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.